Microbot Medical Inc. (NASDAQ: MBOT) announced that Emory University Hospital in Atlanta has become the first hospital worldwide to adopt its LIBERTY Endovascular Robotic System for patient care. The partnership marks the first clinical deployment of the company’s FDA‑cleared, single‑use robotic platform, positioning Microbot as a pioneer in the emerging endovascular robotics market.
The LIBERTY system is a remotely operated, disposable platform that improves procedural precision, reduces radiation exposure, and lowers per‑procedure costs for peripheral endovascular interventions. Microbot received 510(k) clearance on September 8, 2025, and began a limited market release (LMR) on November 5, 2025. The Emory adoption provides a critical reference site and validates the system’s clinical performance in a high‑volume academic setting.
Microbot’s Q3 2025 results showed a net loss of $3.6 million, reflecting the company’s ongoing investment in commercialization and product development. The Emory milestone is a key step toward scaling revenue, as the single‑use model is expected to generate recurring revenue streams once the full market launch is achieved in April 2026 at the Society of Interventional Radiology (SIR) conference.
Analysts have responded positively to the adoption, with a consensus “Buy” rating and an average price target of $12.00, reflecting confidence in the company’s growth trajectory and the market potential of the LIBERTY platform.
CEO Harel Gadot said the Emory partnership “is a major milestone for the entire surgical robotic space” and that the limited market release “will enable us to responsibly support early adopters and lay the groundwork for a full market launch.” Dr. J. David Prologo, Emory’s interventional radiology director, noted that the single‑use, remotely operated design “offers a practical and scalable approach to robotics that supports our operational goals, protects our clinicians, and provides access to quality care.”
Microbot plans to expand the LIBERTY system globally and is pursuing regulatory approvals in other regions. The company’s strong balance sheet, with more cash than debt and a three‑year cash runway, supports continued investment in commercialization while it works toward profitability.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.